Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Parkinson's Disease: Treatment

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...

Parkinson's Disease: Overview

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...

Parkinson Disease l: Introduction

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...

Parkinson Disease ll: Pathophysiology

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

Alterations in Muscle Tone lll

Alterations in Muscle Tone lll

Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Recruitment Strategies across the Spectrum of Neuronal Synuclein Disease.

Annals of neurology·2026

Same author

How PPMI Enabled the First Interventional Platform Trial to Test Therapies in Participants With Early-Stage Neuronal Alpha-Synuclein Disease.

Annals of neurology·2026

Same author

Biologic Frameworks for Synucleinopathies: Contributions of the Parkinson's Progression Markers Initiative.

Annals of neurology·2026

Same author

From Parkinson's Progression Markers Initiative to Parkinson's Precision Medicine Initiative: Still PPMI.

Annals of neurology·2026

Same author

Developing a Virtual Research Environment in the Parkinson's Progression Markers Initiative: myPPMI.

Annals of neurology·2026

Same author

The Role of Coumarins in Drug Discovery: Pharmacological Insights and Structural Innovations.

Current topics in medicinal chemistry·2026

Search research articles

Related Experiment Video

Updated: May 17, 2026

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation

Published on: July 16, 2014

Overcoming obstacles in Parkinson's disease.

Todd B Sherer¹, Sohini Chowdhury, Katherine Peabody

¹The Michael J. Fox Foundation for Parkinson's Research, New York, New York 10163-4777, USA. tsherer@michaeljfox.org

Movement Disorders : Official Journal of the Movement Disorder Society

|November 2, 2012

Summary

Developing new treatments for Parkinson's disease (PD) faces significant hurdles in preclinical and clinical testing, alongside funding challenges. This review explores these critical issues and highlights innovative collaborative and funding strategies to accelerate PD drug development.

More Related Videos

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

Ole Isacson: Development of New Therapies for Parkinson's Disease

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

Related Experiment Videos

Last Updated: May 17, 2026

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation

Published on: July 16, 2014

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

Ole Isacson: Development of New Therapies for Parkinson's Disease

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

Area of Science:

Neuroscience
Pharmacology
Biomedical Research

Background:

Parkinson's disease (PD) requires improved symptomatic and disease-modifying treatments.
Advances in understanding PD etiology have not translated into effective therapies due to drug development challenges.

Purpose of the Study:

To discuss critical challenges in Parkinson's disease drug development.
To explore innovative approaches and new models for overcoming these hurdles.

Main Methods:

Review of systemic challenges in PD drug development.
Analysis of preclinical and clinical testing limitations.
Examination of funding scarcity and risk aversion in late-stage development.

Main Results:

Preclinical testing lacks standardized criteria for therapy advancement.
Clinical trials are often lengthy, costly, and uninformative.
Limited funding and risk aversion hinder late-stage drug development.

Conclusions:

Innovative collaboration and funding models are emerging to address PD drug development challenges.
Overcoming scientific and financial obstacles is crucial for advancing novel PD therapies.